MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD response-adapted consolidation in NDMM

Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC

Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma

Treating patients with multiple myeloma in the real world

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL

KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma

Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma

ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly-diagnosed AL amyloidosis

BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia